April 8, 2026
Halozyme and Vertex sign deal for Hypercon technology
Halozyme Therapeutics’ subsidiary Halozyme Hypercon has signed a global exclusive partnership and licence agreement with Vertex Pharmaceuticals for the former’s Hypercon technology.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.







